Theriva™ Biologics Announces Positive Outcomes from the Second Meeting of the Independent Data Monitoring Committee for VIRAGE, the Company’s Phase 2b Clinical Trial of VCN-01 in Combination with Chemotherapy for Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 31 2025
0mins
Source: Globenewswire
Clinical Trial Update: Theriva Biologics announced that the second Independent Data Monitoring Committee review of the VIRAGE Phase 2b clinical trial found VCN-01 to be well tolerated in patients with newly-diagnosed metastatic pancreatic ductal adenocarcinoma when combined with standard chemotherapy, with adverse events being consistent and manageable.
Future Prospects: The company anticipates releasing topline clinical outcomes data in Q2 2025, which could guide the design of a potential Phase 3 trial based on positive feedback from regulatory agencies.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
